CD33 and acute myeloid leukemia: This led to the approval of gemtuzumab ozogamicin in September 2017 for the treatment of newly diagnosed CD33-positive AML in adults and in pediatrics aged ≥2 years (Fig. 1).61 Currently gemtuzumab is under a phase 1 clinical trial in combination with venetoclax for R/R AML (NCT04070768).